FDA Approves Johnson & Johnson's SPRAVATO® as the First Monotherapy for Treatment-Resistant Depression in Adults Johnson & Johnson has just achieved a major breakthrough in the mental health space, with the approval of SPRAVATO® (esketamine) nasal spray as the first and only monotherapy for adults suffering from...

www.linkedin.com/pulse/fda-ap...

FDA Approves Johnson & Johnson's SPRAVATO® as the First Monotherapy for Treatment-Resistant Depression in Adults

kstrategyand.com/pharma-news

#SPRAVATO #FDAApproval #TRD #NewHopeForDepression #BreakthroughTreatment #Humanteconomy #Humantec #KStrategyand